MPO and chronic myelogenous leukemia, BCR-ABL1 positive: As expected, SA pretreatment did not affect stabilized TOP2A or TOP2B-DNA complexes in K562 cells, a chronic myeloid leukemia-derived cell line that does not express MPO (Supplemental Fig. 3, C and D).